Randall Kaye is joining Neurana Pharmaceuticals as chief medical officer. Kaye was most recently CMO at digital therapeutics developer Click Therapeutics. Previously he held executive roles at SSI Strategy, where he served as CMO of Axsome Therapeutics (NASDAQ: [[ticker:AXSM]]), and at Avanir Pharmaceuticals. Neurana, which is based in San Diego, is advancing its lead drug candidate, tolperisone, as a non-opioid, non-drowsy treatment for muscle spasms; the drug is currently prescribed for that purpose in a number of countries outside of the US.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
